INGENZA LIMITED

Their core work

Ingenza is a synthetic biology and industrial biotechnology SME based in Roslin, Scotland, specializing in the design and engineering of microbial production systems for biomanufacturing. They develop biological platforms that convert engineered microorganisms into cost-effective production hosts for chemicals, pharmaceuticals, and industrial enzymes. Their H2020 work spans microbial chassis engineering (Pseudomonas putida in EmPowerPutida), demonstration of scalable biomanufacturing platforms (SYNBIOMAN), and enzyme engineering for oxidative biocatalysis (OXYTRAIN). As a private company bridging academic research and industrial-scale production, they occupy the critical translational space between lab-stage biology and commercial manufacturing.

What they specialise in

How they've shifted over time

Ingenza's H2020 participation is concentrated in a short window (2015–2017 start dates), making temporal evolution difficult to assess. Their earliest involvement (EmPowerPutida, 2015) focused on fundamental microbial chassis engineering, while SYNBIOMAN (2016) shifted toward commercial demonstration of a biomanufacturing platform — suggesting a progression from research participation toward business validation. Their latest entry, OXYTRAIN (2017), as a third-party partner in a training network, indicates a role as an industry host providing real-world context for early-career researchers in enzyme technology.

Ingenza appears to be moving from research participation toward commercial platform validation and training the next generation of biotech talent, positioning itself as an industry anchor in the UK synthetic biology ecosystem.

How they like to work

Ingenza operates across all consortium roles — coordinator, participant, and third party — which is unusual for an SME with only three projects and suggests adaptability. They coordinated the smaller, commercially-focused SYNBIOMAN (SME Instrument) while joining larger research consortia (EmPowerPutida RIA, OXYTRAIN training network) as a contributor. With 23 unique partners across 10 countries from just 3 projects, they are clearly comfortable in large, multinational consortia and bring an industry translation perspective that academic-heavy teams often lack.

Despite only three projects, Ingenza has built a broad network of 23 partners across 10 countries, reflecting the large consortium sizes typical of RIA and MSCA training networks. Their geographic reach spans multiple European countries, with a likely concentration in Northern and Western European biotech hubs.

What sets them apart

Ingenza fills a specific gap that many EU consortia struggle with: a commercially-driven SME that can take synthetic biology research outputs and translate them into viable biomanufacturing processes. Unlike academic partners, they bring production know-how and a business model for scaling microbial production. For consortium builders, they offer a credible industrial endpoint for biotech projects — the partner who can demonstrate that lab results have a path to market.

Highlights from their portfolio

• EmPowerPutida
  Largest funding (EUR 614,500) in a major RIA consortium — Ingenza's deepest research engagement, focused on re-engineering Pseudomonas putida as an industrial workhorse organism.
• SYNBIOMAN
  Ingenza coordinated this SME Instrument Phase 1 project, demonstrating their own biomanufacturing platform's commercial feasibility — a direct indicator of their business ambitions.
• OXYTRAIN
  MSCA training network role as third-party industry host shows Ingenza's commitment to talent pipeline development and enzyme technology diversification.